Skip to main content
Delfa

← All trials/NCT07043361

Semaglutide

Completed

Efficacy of Semaglutide in Glycemic Control, Weight Loss, and Improving Lipidogram- Role of Baseline Vitamin D Levels

Efficacy of Semaglutide in Glycemic Control, Weight Loss, and Improving Lipid Profile- the Role of Baseline Vitamin D Levels

Asset

Semaglutide

GLP-1 agonist

Listed sites

1

Recruiting sites

-

Actual enrollment

5,300

Study population

Type 2 diabetes

Eligibility highlights

-

Primary endpoints

BMI, changeHbA1c, changeLipid control

Registered trial locations

Locations reported to ClinicalTrials.gov for this trial snapshot. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT07043361
Org study ID0034-23-LEU
Secondary IDNon applicableLeumit health care system

Timeline

Milestones

Study start2023-12-18actual
Primary completion2024-12-21actual
Study completion2025-04-30actual
Study first posted2025-06-29actual
Last update posted2025-07-09actual

Assets

Investigational agents

Who this study enrolls

Type 2 diabetes

Who can enroll

Minimum age18 Years
Maximum age80 Years
SexAll
Healthy volunteersNot accepted
Sampling methodNon probability sample

Study population text

diabetic patients on semaglutide treatment and with available baseline vitamin D levels

Inclusion criteria

Diabetes type II treated with semaglutide
Available baseline vitamin D levels

Exclusion criteria

Missing serum 25-hydroxyvitamin D (25[OH]D) data
Pregnant or lactating females

Endpoints (3)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Weight & body composition
1
Glycemic / diabetes
1
Cardiometabolic biomarkers
1

Weight & body composition

1 endpoint
Primary/protocol endpoint

relative weight loss measured by BMI

Time frame:12 months from semaglutide initiation

BMI, change

percent change from baseline, improvement

Glycemic / diabetes

1 endpoint
Primary/protocol endpoint

glycemic control using Hgb1C

Time frame:12 months from semaglutide initiation

HbA1c, change

change from baseline, improvement

LOINC 4548-4

Cardiometabolic biomarkers

1 endpoint
Primary/protocol endpoint

lipid control using LDL and TG

Time frame:12 months from semaglutide initiation

descriptive, improvement

Publications (17)

Bibliography

Records linked to this trial through ClinicalTrials.gov references, PubMed NCT search, and curated study seeds. 'Canonical' marks design/result papers; others are registry references or candidates.

Registry references + supporting bibliography

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2
Snapshot dateJuly 6, 2026
Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)
Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 6, 2026 snapshot.